Table II.
Comparison of clinicopathological features between non-DEL and DEL subgroup in 87 patients with diffuse large B-cell lymphoma.
| Characteristic | Total n=87 (%) | Non-DEL n=51 (%) | DEL n=36 (%) | P-value |
|---|---|---|---|---|
| Median age (range) | 55 (20–84) | 53 (24–84) | 57 (20–81) | |
| Age >60 years | 30 (34) | 16 (31) | 14 (39) | 0.499 |
| Male:female | 46:41 | 25:26 | 21:15 | 0.531 |
| Ann Arbor stage III/IV | 42 (42) | 18 (35) | 24 (67) | 0.004a |
| Elevated LDH | 47 (48) | 19 (37) | 28 (78) | 0.000a |
| ENS >2 | 20 (23) | 6 (12) | 14 (39) | 0.004a |
| PS score >1 | 25 (29) | 9 (18) | 17 (47) | 0.004a |
| IPI score ≥3 | 19 (22) | 6 (12) | 14 (39) | 0.004a |
| BM involvement+ | 8 (9) | 2 (4) | 6 (17) | 0.061 |
| CNS involvement+ | 5 (6) | 2 (4) | 3 (8) | 0.645 |
| B symptom | 9 (10) | 3 (6) | 6 (17) | 0.154 |
| GCB:non-GCB subtype | 22:65 | 18:33 | 4:32 | 0.012a |
| Ki67 ≥80% | 27 (31) | 15 (29) | 12 (33) | 0.851 |
| ORR | 66 (76) | 46 (90) | 20 (56) | 0.000a |
a
Pearson's Chi-Square Test. DEL, double-expressor lymphoma; LDH, lactate dehydrogenase; ENS, extra nodal sites; PS score, performance status score; IPI score, international prognostic index score; BM+, bone marrow involved; CNS+, central nervous system involved; GCB, germinal center B-cell; ORR, objective response rate.